Details of Disease

General Information of Disease (ID: DISO250N)

Disease Name Cerebral ischemia
Disease Class 8B11: Cerebral ischaemic stroke
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISO250N: Cerebral ischemia
ICD Code
ICD-11
ICD-11: 8B11
ICD-10
ICD-10: I67.8
Expand ICD-11
'8B1Z
Expand ICD-10
'I67.8
Disease Identifiers
MONDO ID
MONDO_0005299
MESH ID
D002545
UMLS CUI
C0917798
MedGen ID
182975
HPO ID
HP:0002637
SNOMED CT ID
287731003

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
PEG-bHb-CO DMJ38X9 Phase 2/3 NA [1]
BMS-986177 DM4QHZS Phase 2 Small molecular drug [2]
DM199 DM0157T Phase 2 Recombinant protein [3]
SonoLysis Prolyse DMPXY0H Phase 2 NA [4]
ACT017 DMEU86T Phase 1/2 Small molecular drug [5]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1 DMZ4B3W Patented Small molecular drug [6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT03766581) A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel (AXIOMATIC-SSP). U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT04123613) Multiple Doses of DM199 in Patients With Chronic Kidney Disease. U.S. National Institutes of Health.
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004567)
5 ClinicalTrials.gov (NCT03803007) Acute Ischemic Stroke Interventional Study (ACTIMIS). U.S. National Institutes of Health.
6 Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.